報價延遲最少15分鐘:2025/06/03 19:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.05/0.60
|
|
企業價值
129.81M
|
| 資產負債 |
|
每股賬面淨值
0.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
53.40M
|
|
每股收益
0.80
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 19:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I. |